J&J-Bound Reed Reaches End Of The Road As Sanofi R&D Chief
Staying In Big Pharma
Executive Summary
The French drugmaker has begun an external and internal search to succeed John Reed who is heading for Johnson & Johnson after an up-and-down five years as Sanofi’s R&D chief.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: Leqembi bodes well for Biogen; AbbVie predicts US Humira erosion; Sanofi’s R&D chief moves on; Roche’s ophthalmology plans; and Scrip Asks what 2023 holds for AI in pharma.
Sanofi Gains New Innate Program In Expanded Collaboration
Deal Snapshot: Innate will receive €25m up front from Sanofi for an exclusive license to a new natural killer (NK) cell engager program and options to two additional targets.
RSV Market Shake Up Starts As Sanofi And AZ’s Beyfortus Wins First Approval
The firms’ monoclonal antibody has received the EU green light just months after a positive CHMP opinion with observers projecting billions in peak sales as it becomes the first new RSV prophylactic in decades.